Conatus Pharmaceuticals Initiates Phase 2 Trial In Patients With Liver Cirrhosis And Separate Open Label Phase 2 Trial In Cirrhosis Patients With Portal Hypertension
September 02, 2014 at 07:03 AM EDT
Conatus Pharmaceuticals Inc. (Nasdaq: CNAT), a biotechnology company focused on the development and commercialization of novel medicines ...